P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA

Geahča maid

• Current status and research directions in acute myeloid leukemia
  Dahkki: Hagop Kantarjian, et al.
  Almmustuhtton: (2024-09-01)
• P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA
  Dahkki: Aram Bidikian, et al.
  Almmustuhtton: (2023-08-01)
• Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia
  Dahkki: Roberta S. Azevedo, et al.
  Almmustuhtton: (2025-06-01)
• P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
  Dahkki: Daniel Nguyen, et al.
  Almmustuhtton: (2023-08-01)
• Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin
  Dahkki: Jayastu Senapati, et al.
  Almmustuhtton: (2024-08-01)